Published in Leuk Res on February 12, 2012
Actin engine in immunological synapse. Immune Netw (2012) 0.81
WDR5 high expression and its effect on tumorigenesis in leukemia. Oncotarget (2016) 0.77
Multivariate models from RNA-Seq SNVs yield candidate molecular targets for biomarker discovery: SNV-DA. BMC Genomics (2016) 0.76
Does B cell receptor signaling in chronic lymphocytic leukaemia cells differ from that in other B cell types? Scientifica (Cairo) (2014) 0.75
Genome-scale analysis to identify prognostic markers in patients with early-stage pancreatic ductal adenocarcinoma after pancreaticoduodenectomy. Onco Targets Ther (2017) 0.75
Multilevel dysregulation of STAT3 activation in anaplastic lymphoma kinase-positive T/null-cell lymphoma. J Immunol (2002) 1.89
Cladribine, but not fludarabine, added to daunorubicin and cytarabine during induction prolongs survival of patients with acute myeloid leukemia: a multicenter, randomized phase III study. J Clin Oncol (2012) 1.56
Rozrolimupab, a mixture of 25 recombinant human monoclonal RhD antibodies, in the treatment of primary immune thrombocytopenia. Blood (2012) 1.50
T-cell abnormalities are present at high frequencies in patients with hypereosinophilic syndrome. Haematologica (2009) 1.20
Ofatumumab monotherapy in rituximab-refractory follicular lymphoma: results from a multicenter study. Blood (2012) 1.09
Expression and oncogenic role of Brk (PTK6/Sik) protein tyrosine kinase in lymphocytes. Am J Pathol (2006) 0.97
IL-6 and IL-10 promoter gene polymorphisms do not associate with the susceptibility for multiple myeloma. Immunol Lett (2005) 0.97
Proinflammatory chemokine gene expression influences survival of patients with non-Hodgkin's lymphoma. Folia Histochem Cytobiol (2011) 0.96
Immunoglobulin D myeloma--problems with diagnosing and staging (own experience and literature review). Leuk Lymphoma (2005) 0.92
TGF-beta1 gene polymorphisms influence the course of the disease in non-Hodgkin's lymphoma patients. Cytokine (2006) 0.91
Effective treatment of leukemia cutis with combination of rituximab, cladribine, and cyclophosphamide in patient with B-cell chronic lymphocytic leukemia. Ann Hematol (2010) 0.90
Expression of microRNA-331 can be used as a predictor for response to therapy and survival in acute myeloid leukemia patients. Biomark Med (2015) 0.90
Expression of complement regulatory proteins: CD46, CD55, and CD59 and response to rituximab in patients with CD20+ non-Hodgkin's lymphoma. Med Oncol (2009) 0.90
microRNAs: fine tuning of erythropoiesis. Cell Mol Biol Lett (2012) 0.89
A - 308 promoter polymorphism of tumor necrosis factor alpha gene does not associate with the susceptibility to psoriasis vulgaris. No difference either between psoriasis type I and type II patients. Acta Dermatovenerol Alp Pannonica Adriat (2006) 0.89
Angiogenesis measured by expression of CD34 antigen in lymph nodes of patients with non-Hodgkin's lymphoma. Folia Histochem Cytobiol (2004) 0.87
Complete cytogenetic and molecular response after imatinib treatment for chronic myeloid leukemia in a patient with atypical karyotype and BCR-ABL b2a3 transcript. Cancer Genet Cytogenet (2007) 0.87
Prognostic significance of Ki-67 antigen expression in non-Hodgkin's lymphomas. Anticancer Res (2008) 0.86
Palmitoylation of MPP1 (membrane-palmitoylated protein 1)/p55 is crucial for lateral membrane organization in erythroid cells. J Biol Chem (2012) 0.86
Primary pulmonary diffuse large B-cell lymphoma. Am J Hematol (2011) 0.86
Elevated YB-1 expression is a new unfavorable prognostic factor in non-Hodgkin's lymphomas. Anticancer Res (2011) 0.85
IFN-gamma promoter gene polymorphism in psoriasis vulgaris. Biomarkers (2008) 0.85
Changes in spectrin organisation in leukaemic and lymphoid cells upon chemotherapy. Biochem Pharmacol (2005) 0.85
Circulating sCD138 and some angiogenesis-involved cytokines help to anticipate the disease progression of early-stage B-cell chronic lymphocytic leukemia. Mediators Inflamm (2006) 0.85
Increased angiogenesis in cutaneous T-cell lymphomas. Pathol Oncol Res (2004) 0.85
Expression of PIM-2 and NF-κB genes is increased in patients with acute myeloid leukemia (AML) and acute lymphoblastic leukemia (ALL) and is associated with complete remission rate and overall survival. Postepy Hig Med Dosw (Online) (2013) 0.83
Comparison of cladribine plus prednisone with chlorambucil plus prednisone in patients with chronic lymphocytic leukemia. Final report of the Polish Adult Leukemia Group (PALG CLL1). Med Sci Monit (2005) 0.83
IL-6 and IL-10 promoter gene polymorphisms in psoriasis vulgaris. Acta Derm Venereol (2008) 0.82
Unclassifiable small B-cell lymphoma with marked plasmacytic differentiation and Mott cell formation. Leuk Lymphoma (2013) 0.82
IL-17F gene polymorphism is associated with susceptibility to acute myeloid leukemia. J Cancer Res Clin Oncol (2014) 0.82
[Nasopharyngeal carcinoma coexistent with lymph node tuberculosis, diagnostic difficulties--case report]. Otolaryngol Pol (2005) 0.82
Central nervous system prophylaxis with intrathecal liposomal cytarabine in diffuse large B-cell lymphomas. Pol Arch Med Wewn (2013) 0.81
A novel L1340P mutation in the ANK1 gene is associated with hereditary spherocytosis? Br J Haematol (2014) 0.81
Increased percentage of CD8+CD28- suppressor lymphocytes in peripheral blood and skin infiltrates correlates with advanced disease in patients with cutaneous T-cell lymphomas. Postepy Hig Med Dosw (Online) (2009) 0.81
Variations in suppressor molecule ctla-4 gene are related to susceptibility to multiple myeloma in a polish population. Pathol Oncol Res (2011) 0.81
High CD74 expression correlates with ZAP70 expression in B cell chronic lymphocytic leukemia patients. Med Oncol (2013) 0.81
Comparison of positron emission tomography/computed tomography with classical contrast-enhanced computed tomography in the initial staging of Hodgkin lymphoma. Leuk Lymphoma (2014) 0.81
Chemokines and left ventricular function in patients with acute myocardial infarction. Eur J Intern Med (2007) 0.81
Polymorphisms of TNF and IL-10 genes and clinical outcome of patients with chronic lymphocytic leukemia. Genes Chromosomes Cancer (2012) 0.81
VEGF and bFGF gene polymorphisms in patients with non-Hodgkin's lymphoma. Biomed Res Int (2013) 0.81
Premature cardiovascular mortality in lymphoma patients treated with (R)-CHOP regimen - a national multicenter study. Int J Cardiol (2013) 0.80
[Expression of serum vascular endothelial growth factor correlates with clinical outcome in multiple myeloma]. Pol Arch Med Wewn (2003) 0.80
The achievement of complete molecular remission after autologous stem cell transplantation for T-cell lymphoma with associated hypereosinophilia, rare aberration t(6;11) and elevated IL-4 and IgE. Haematologica (2006) 0.79
Aggregation of spectrin and PKCtheta is an early hallmark of fludarabine/mitoxantrone/dexamethasone-induced apoptosis in Jurkat T and HL60 cells. Mol Cell Biochem (2010) 0.79
Hematopoietic stem cell transplantation for T315I-mutated chronic myelogenous leukemia. Ann Transplant (2010) 0.79
High intracellular content of cyclin-dependent kinase inhibitor p27(Kip1) in early- and intermediate stage B-cell chronic lymphocytic leukemia lymphocytes predicts rapid progression of the disease. Eur J Haematol (2009) 0.79
Infectious complications in patients with acute myeloid leukemia treated according to the protocol with daunorubicin and cytarabine with or without addition of cladribine. A multicenter study by the Polish Adult Leukemia Group (PALG). Int J Infect Dis (2009) 0.79
Positive correlation between cyclooxygenase-2 and ABC-transporter expression in non-Hodgkin's lymphomas. Oncol Rep (2009) 0.79
Expression of SHP-1 phosphatase indicates post-germinal center cell derivation of B-cell posttransplant lymphoproliferative disorders. Lab Invest (2002) 0.79
Increased expression of metalloproteinase-2 and -9 (MMP-2, MMP-9), tissue inhibitor of metalloproteinase-1 and -2 (TIMP-1, TIMP-2), and EMMPRIN (CD147) in multiple myeloma. Hematology (2015) 0.78
[Circulating endothelial cells, endothelial precursors, VEGF and bFGF concentrations in patients with acute leukemias, lymphomas and myelomas]. Pol Arch Med Wewn (2005) 0.78
A risk of essential thrombocythemia in carriers of constitutional CHEK2 gene mutations. Haematologica (2011) 0.78
Kinetics of chemokines in acute myocardial infarction. Kardiol Pol (2005) 0.78
Heart rate variability and heart rate turbulence in patients with hematologic malignancies subjected to high-dose chemotherapy in the course of hematopoietic stem cell transplantation. Ann Noninvasive Electrocardiol (2013) 0.78
Asymmetric dimethylarginine in hematological malignancies: a preliminary study. Leuk Lymphoma (2008) 0.78
Increased expression of vascular endothelial growth factor (VEGF) in bone marrow of patients with myeloproliferative disorders (MPD). Pathol Oncol Res (2003) 0.78
Malignant melanoma with gall bladder metastasis as a second neoplasm in the course of prostate cancer. Pathol Oncol Res (2004) 0.78
[Vascular endothelial growth factor (VEGF) serum concentration in non-Hodgkin's lymphoma patients]. Pol Arch Med Wewn (2004) 0.78
Expression of cyclin A and bone morphogenetic protein receptors and response to induction therapy in patients with acute leukemias. Leuk Lymphoma (2011) 0.78
Density of intranodal lymphatics and VEGF-C expression in B-cell lymphoma and reactive lymph nodes. Folia Histochem Cytobiol (2006) 0.78
Expression of Eph A4, Eph B2 and Eph B4 receptors in AML. Pathol Oncol Res (2014) 0.78
High incidence of ancestral HLA haplotype 8.1 and monoclonal incomplete DH-JH immunoglobulin heavy chain gene rearrangement in persistent polyclonal B-cell lymphocytosis. Ann Hematol (2008) 0.78
TGF-beta(1) gene polymorphism in psoriasis vulgaris. Cytokine (2007) 0.78
[Expression of Fas receptor and soluble Fas ligand (sFasL) concentration in acute leukemia]. Pol Arch Med Wewn (2002) 0.78
[Liposomal cytarabine in prophylaxis of the central nervous system involvement in rare aggresive lymphomas]. Przegl Lek (2013) 0.78
High density of peritumoral lymphatic vessels measured by D2-40/podoplanin and LYVE-1 expression in gastric cancer patients: an excellent prognostic indicator or a false friend? Gastric Cancer (2012) 0.77
VEGF and bFGF gene polymorphisms in Polish patients with B-CLL. Med Oncol (2013) 0.77
[Familial incidence of myelodysplastic syndromes]. Wiad Lek (2006) 0.77
Echocardiographic assessment of myocardial function in workers occupationally exposed to lead without clinically evident heart disease. Environ Toxicol Pharmacol (2013) 0.77
Altered plasma fibrin clot properties and fibrinolysis in patients with multiple myeloma. Eur J Clin Invest (2014) 0.77